On the morning of May 15, 2026, the Ministry of Health of the Democratic Republic of the Congo confirmed what laboratory scientists at the Institut National de Recherche Biomédical in Kinshasa had feared: Ebola was back. Not the Zaire strain the world has learned to respond to with emergency vaccines, but the Bundibugyo virus (BDBV) — a rarer, less-understood species of Orthoebolavirus for which no approved vaccine or treatment exists. Within 48 hours, the outbreak had crossed an international border into Uganda. Within 72 hours, the World Health Organization had declared a Public Health Emergency of International Concern — the highest alert level in the global health system.

By May 25, 2026, the numbers told a grim story: over 906 suspected cases and 223 suspected deaths in DRC alone, with 105 confirmed cases and 10 confirmed deaths — the discrepancy between suspected and confirmed figures reflecting the profound challenges of laboratory access in conflict-affected northeastern DRC. In Uganda, seven confirmed cases including two Kampala-based healthcare workers, one death, and a travel-linked chain suggesting the virus had already seeded itself in the East African regional hub.

This is now the third-largest Ebola outbreak in recorded history, trailing only the catastrophic 2014–2016 West Africa outbreak (28,000+ cases) and the 2018–2020 DRC outbreak. And it is accelerating.

Not all Ebola outbreaks are equal. The strain driving this crisis — Bundibugyo virus (BDBV), species Orthoebolavirus bundibugyoense — was first identified in 2007 in Bundibugyo District, Uganda, where it killed 37 of 149 confirmed patients. It is the second-rarest of the five known Ebola virus species, and it presents a specific and severe challenge: there is no approved vaccine and no approved antiviral treatment.

The approved vaccine rVSV-ZEBOV (Ervebo) and monoclonal antibody therapies like Inmazeb and Ebanga were developed specifically against the Zaire strain — the strain responsible for the 2014–2016 West Africa disaster. Against Bundibugyo, they offer no proven protection. This is the equivalent of having a flu vaccine that works against Influenza A but provides no coverage against Influenza B — except the stakes are measured in hemorrhagic fever deaths.

The incubation period runs from 2 to 21 days — meaning an infected traveler can board an international flight, clear customs, check into a hotel in Paris, London, or New York, and not show symptoms until three weeks later. During that "dry" phase — characterized by fever, myalgias, and fatigue — the virus is present but transmission risk is lower. It is the second "wet" phase — diarrhea, vomiting, and hemorrhage — that is both the most deadly and most contagious. The 2014 Dallas case illustrated precisely this risk: a Liberian national infected in West Africa presented at a Texas emergency room, was sent home on antibiotics, and returned days later in the wet phase, infecting two healthcare workers.

There is a bitter irony at the heart of the 2026 Ebola crisis. The world is better equipped than ever to detect, isolate, and contain Ebola outbreaks — and yet the political decisions made in 2025 have systematically dismantled the early-warning infrastructure that makes that detection possible.

The chain of failures begins with the dismantling of USAID under the Trump administration. USAID was, for decades, the primary funder of community health surveillance networks across sub-Saharan Africa. In the DRC alone, USAID-funded programs supported the rapid response teams, laboratory reagent stockpiles, and community health workers who have historically served as the first line of detection. In 2025, those programs were cancelled. "Everything stalled while the outbreak continued," a former USAID official told CNN. By the time the 2026 outbreak began, almost everyone on the USAID team that had managed the previous DRC Ebola response had been fired.

The second rupture came with the US withdrawal from the World Health Organization. The withdrawal — undertaken in 2025 — means the United States no longer receives real-time epidemiological intelligence through WHO's official reporting channels. Informal contact continues, but the structured information flows that allowed CDC to act pre-emptively during previous outbreaks are broken. As one former CDC official told CNN: "Withdrawing from the WHO just means the US government and CDC are generally more out of the loop with information flows. They're not part of the conversation in the same way. And I think that makes America less safe."

The third compounding factor is the conflict environment within which the outbreak is unfolding. Ituri Province and Nord-Kivu — the epicentres of the DRC outbreak — are among the most dangerous and inaccessible regions in the world. Armed groups have repeatedly attacked health workers during previous outbreaks. Community distrust of government and international health agencies runs deep, partly as a legacy of past outbreaks and partly due to active disinformation. The burning of hospital tents by citizens on May 22 is not an aberration — it is a symptom of a public health system in which communities have been given little reason to trust the authorities asking them to comply.

Kampala's exposure adds a fourth dimension: Uganda is a regional transit hub. Entebbe International Airport serves direct routes to London Heathrow, Dubai International, Amsterdam Schiphol, and Nairobi — all of which are themselves global hubs. The two infected Kampala healthcare workers were employed at a private hospital, raising the spectre of nosocomial spread in an urban medical setting — the nightmare scenario that turned the 2014 outbreak from a rural crisis into a global emergency.

One of the most alarming features of the 2026 outbreak is the speed of geographic expansion within DRC. What began in Ituri Province has now been confirmed in Nord-Kivu, Sud-Kivu, and most recently a new province confirmed on May 25 — meaning the virus is tracking along trade and population movement corridors, rather than being contained at the source.

The official WHO risk assessment — as of May 25 — rates the outbreak as Very High at the national level (DRC), High at the regional level, and Low at the global level. This framework is technically accurate but dangerously easy to misread. "Low global risk" does not mean "no global risk." It means that, at this moment, the structural conditions for widespread global transmission are not in place. Those conditions can change rapidly — and the institutional safeguards that would normally provide the earliest warning have been weakened.

This assessment matters for a specific reason: the response capacity of the United States has been materially reduced at precisely the moment it is most needed. The CDC has brought hundreds of personnel into the emergency response — but the pre-positioned supplies, surveillance networks, and community health infrastructure that allowed rapid containment in 2014–2016 have been significantly depleted. A State Department official denied that the administration's changes hampered the response. The epidemiological timeline suggests otherwise.

The most urgent scientific challenge is the absence of any approved medical countermeasure against Bundibugyo virus. Clinical trials are now being developed jointly between WHO, Africa CDC, and the Collaborative Open Research Consortium on Filoviruses (CORC-F). Several candidate vaccines are in the pipeline, and work on candidate antivirals is ongoing — but "in the pipeline" is not "in the field." The gap between a promising clinical trial result and a scalable emergency deployment is measured in months to years, not weeks.

The contrast with the COVID-19 vaccine development — where mRNA platform technology allowed candidate vaccines to reach Phase III trials in months rather than years — is instructive. No equivalent mRNA-based Ebola vaccine platform is currently deployed. Researchers at Oxford, the US NIH, and several African institutions are working on cross-reactive filovirus vaccines that might offer partial protection against multiple Ebola strains, but these remain years from emergency authorization.

The current approach relies on ring vaccination — using the Zaire-strain vaccines on close contacts of confirmed cases as a protective measure even though their efficacy against Bundibugyo is unproven. This is not a clinical decision based on evidence; it is a decision made from desperation, in the absence of better options.

Every Ebola outbreak of the past three decades has produced the same post-mortem: the response came too late, was under-resourced, and failed to adequately invest in the communities it purported to protect. The 2014–2016 West Africa outbreak killed 11,325 people and infected 28,616 — a catastrophe that could have been contained if the WHO had declared a PHEIC four to six months earlier than it did. A subsequent review found that WHO's decision-making had been influenced by concerns about the economic impact of a PHEIC declaration on the affected countries. Politics delayed science. People died.

The 2018–2020 DRC outbreak was ultimately contained — at the cost of nearly 2,300 lives and two years of brutal fieldwork — in part because the Zaire vaccine existed and could be deployed via ring vaccination. No such tool exists for 2026. The lesson of 2018–2020 is therefore both reassuring (containment is possible even in conflict zones) and alarming (it required resources, funding, and international cooperation that are now substantially diminished).

Responsible analysis requires confronting the scenarios that policymakers prefer not to discuss publicly. The following is not alarmism — it is the kind of contingency thinking that the global health community conducts internally, and that the public deserves to engage with honestly.

Scenario A — Controlled Containment: Strong community engagement, adequate PPE supply chains, accelerated ring vaccination even with unproven Bundibugyo efficacy, and robust contact tracing. Historical precedent: the 2022 Uganda Sudan-strain outbreak, contained in approximately 77 days with 164 total cases. Probability: possible but requiring immediate and sustained international resource commitment.

Scenario B — Prolonged Endemic Outbreak: Partial containment. The virus becomes endemic to conflict-affected provinces, flaring periodically. International spread limited to isolated cases in transit hubs that are rapidly identified and isolated. Historical precedent: the first year of the 2018–2020 DRC outbreak before the vaccine rollout. Duration: 18–24 months minimum. Total cases: potentially 3,000–5,000.

Scenario C — Uncontrolled Regional Spread: The nightmare. A breakdown in contact tracing, community resistance preventing isolation, and a significant nosocomial cluster in Kampala seeding cases into international travelers. The conditions for this scenario are not hypothetical — they are partially in place. The probability of this scenario remains low but is not zero, and the degradation of the early-warning system means that the moment of detection may come later than it should.

The 2026 Ebola outbreak is not beyond control. Every previous Ebola outbreak has been stopped. But stopping this one requires decisions — political, financial, and institutional — that cannot be deferred. The following is a ZTT LLC policy framework, drawing on WHO guidance, CDC recommendations, and independent expert assessment.

The 2026 Ebola outbreak is, in the most precise sense, a political disease. The virus itself is biological — a 19-kilobase RNA genome wrapped in a glycoprotein envelope, ancient and indifferent. But the conditions that allowed it to reach 906 suspected cases in ten days, that left it without a vaccine, that burned the community health networks that would have detected it earlier and contained it faster — those conditions are political. They were created by deliberate decisions made in Washington, D.C. and Geneva in 2025.

The WHO Director-General said on May 25 that the outbreak "will get worse before it gets better." He is almost certainly correct. The question — the only question that matters now — is how much worse, and for how long. The answer depends on whether the international community can summon the political will and financial resources to respond with the urgency that a third-largest-ever Ebola outbreak demands.

History offers two templates. In 2014, the world waited too long, and 11,325 people died. In 2018–2020, the world mobilized imperfectly but adequately, and the outbreak was contained at under 3,500 cases. The 2026 outbreak begins from a worse institutional baseline than either of those precedents. That does not make catastrophe inevitable. It makes vigilance, funding, and speed more important than they have ever been.

The virus does not respect borders, politics, or budget cycles. It only respects the speed and completeness of the response. The window to shape which historical template the 2026 outbreak follows is open now. It will not remain open indefinitely.